148 related articles for article (PubMed ID: 20927639)
1. Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.
Vidal L; Magem M; Barlow C; Pardo B; Florez A; Montes A; Garcia M; Judson I; Lebedinsky C; Kaye SB; Salazar R
Invest New Drugs; 2012 Apr; 30(2):616-28. PubMed ID: 20927639
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
Chu Q; Mita A; Forouzesh B; Tolcher AW; Schwartz G; Nieto A; Soto-Matos A; Alfaro V; Lebedinsky C; Rowinsky EK
Clin Cancer Res; 2010 May; 16(9):2656-65. PubMed ID: 20406837
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.
Sessa C; Del Conte G; Christinat A; Cresta S; Perotti A; Gallerani E; Lardelli P; Kahatt C; Alfaro V; Iglesias JL; Fernández-Teruel C; Gianni L
Invest New Drugs; 2013 Oct; 31(5):1236-43. PubMed ID: 23467812
[TBL] [Abstract][Full Text] [Related]
4. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.
Gore L; Rivera E; Basche M; Moulder-Thompson SL; Li J; Eppers S; Grolnic S; O'Bryant C; Cleere D; Elsayed YA; Eckhardt SG
Invest New Drugs; 2012 Oct; 30(5):1942-9. PubMed ID: 21931969
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.
von Mehren M; Bookman M; Meropol NJ; Weiner LM; Sherman E; Li J; Knoblauch R; Parekh T; Cohen RB
Cancer Chemother Pharmacol; 2015 May; 75(5):1047-55. PubMed ID: 25791363
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Forouzesh B; Hidalgo M; Chu Q; Mita A; Mita M; Schwartz G; Jimeno J; Gómez J; Alfaro V; Lebedinsky C; Zintl P; Rowinsky EK
Clin Cancer Res; 2009 May; 15(10):3591-9. PubMed ID: 19417019
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
Messersmith WA; Jimeno A; Ettinger D; Laheru D; Brahmer J; Lansey D; Khan Y; Donehower RC; Elsayed Y; Zannikos P; Hidalgo M
Cancer Chemother Pharmacol; 2008 Dec; 63(1):181-8. PubMed ID: 18379785
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM
J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas.
Salazar R; Plummer R; Oaknin A; Robinson A; Pardo B; Soto-Matos A; Yovine A; Szyldergemajn S; Calvert AH
Invest New Drugs; 2011 Dec; 29(6):1406-13. PubMed ID: 20623160
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors.
Salazar R; Calles A; Gil M; Durán I; García M; Hidalgo M; Coronado C; Alfaro V; Siguero M; Fernández-Teruel C; Prados R; Calvo E
Invest New Drugs; 2014 Aug; 32(4):644-52. PubMed ID: 24535315
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
Heath EI; Blumenschein GR; Cohen RB; Lorusso PM; Loconte NK; Kim ST; Ruiz-Garcia A; Chao RC; Wilding G
Cancer Chemother Pharmacol; 2011 Sep; 68(3):703-12. PubMed ID: 21140147
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.
Pardo B; Salazar R; Ciruelos E; Cortés-Funes H; García M; Majem M; Montes A; Cuadra C; Soto-Matos A; Lebedinsky C; Alfaro V; Paz-Ares L
Med Oncol; 2012 Sep; 29(3):2240-50. PubMed ID: 21660618
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
Taamma A; Misset JL; Riofrio M; Guzman C; Brain E; Lopez Lazaro L; Rosing H; Jimeno JM; Cvitkovic E
J Clin Oncol; 2001 Mar; 19(5):1256-65. PubMed ID: 11230466
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.
Paz-Ares L; López-Pousa A; Poveda A; Balañá C; Ciruelos E; Bellmunt J; del Muro JG; Provencio M; Casado A; Rivera-Herrero F; Izquierdo MA; Nieto A; Tanović A; Cortes-Funes H; Buesa JM
Invest New Drugs; 2012 Apr; 30(2):729-40. PubMed ID: 20960029
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
Sessa C; Cresta S; Noberasco C; Capri G; Gallerani E; De Braud F; Zucchetti M; D'Incalci M; Locatelli A; Marsoni S; Corradino I; Minoia C; Zintl P; Gianni L
Eur J Cancer; 2009 Aug; 45(12):2116-22. PubMed ID: 19419856
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Twelves C; Hoekman K; Bowman A; Vermorken JB; Anthoney A; Smyth J; van Kesteren C; Beijnen JH; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
Eur J Cancer; 2003 Sep; 39(13):1842-51. PubMed ID: 12932661
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
van Kesteren C; Twelves C; Bowman A; Hoekman K; López-Lázaro L; Jimeno J; Guzman C; Mathôt RA; Simpson A; Vermorken JB; Smyth J; Schellens JH; Hillebrand MJ; Rosing H; Beijnen JH
Anticancer Drugs; 2002 Apr; 13(4):381-93. PubMed ID: 11984084
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.
von Mehren M; Schilder RJ; Cheng JD; Temmer E; Cardoso TM; Renshaw FG; Bayever E; Zannikos P; Yuan Z; Cohen RB
Ann Oncol; 2008 Oct; 19(10):1802-9. PubMed ID: 18497430
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
